BIOCYTOGEN-B (02315) recently announced multiple collaborations and R&D progress with Merck, Tubulis, and IDEAYA, drawing significant market attention and highlighting the company's platform capabilities in antibody drug development and innovative delivery technologies, as well as the effectiveness of its international partnerships.

Recently, BIOCYTOGEN-B's partner IDEAYA Biosciences prominently featured their jointly developed bispecific antibody-drug conjugate (bsADC) IDE034 (BCG034) at its 10th anniversary R&D day. The drug is developed based on BIOCYTOGEN-B's RenLite® platform, targeting B7-H3 and PTK7, and incorporates the company's novel Linker & Payload platform BLD1102. Preclinical data demonstrate significant efficacy in specific tumor models, particularly showing tumor-specific synergistic effects when combined with PARG inhibitor IDE161. IDEAYA plans to submit an Investigational New Drug application in the fourth quarter of this year, with indications intended to cover multiple cancer types including lung cancer and colorectal cancer.

Additionally, BIOCYTOGEN-B recently announced successive partnership agreements with German company Tubulis and global technology leader Merck. Tubulis intends to license BIOCYTOGEN-B's proprietary fully human antibodies to advance the development and commercialization of its ADC products. BIOCYTOGEN-B will receive an upfront payment and will be eligible for development, regulatory, and commercialization milestone payments, as well as single-digit net sales royalties.

The collaboration with Merck focuses on advancing the development of antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP).